Research
Hormonal
Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.
If you are struggling to lose weight with Semaglutide, ask your doctor about Tirzepatide. Clinical trials show it can lead to greater weight loss (around 21%) compared to Semaglutide (around 14%) in obese patients without diabetes. However, be aware that it may be more expensive and less likely to be covered by insurance.
StrongSupportsVERY_HIGH confidence
Over 72 weeks, obese patients without type 2 diabetes who were treated with tirzepatide achieved a body weight reduction of −20.9%, while those treated with semaglutide achieved a reduction of 13.7%.
Why this rating
Based on cited high-quality clinical trials (SURMOUNT series) with p < 0.001.
Source
Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland
Klaudia Nowak et al. · Healthcare · 2025
cohort · n=36399Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →